Generer rapport
Medican A/S
Skovgårdsvej 27, 3200 Helsinge, CVR 39015684
Virksomhedsform
Aktieselskab
Etableret
2017
Størrelse
Små
Ansatte
16
Omsætning
-
DKK
Bruttofortj.
-9.237.284
DKK
Primært resultat (EBIT)
-23.510.195
DKK
Årets resultat
-39.688.347
DKK
Egenkapital
16
MDKK
Den viste virksomhed har en særlig status
Bemærk, at virksomheden er registreret med følgende status: Under konkurs. annonce
Flere nøgletal og analyser?
Med en Bisbase Premium konto får du flere nøgletal for både virksomheder, koncerner og brancher samt adgang til eksklusive brancher indeholdende virksomheder nøje sammensat af eksperter. Og vil du lave dine egne analyser kan du også det! Det tager få minutter at få adgang - og det behøver ikke at koste dig noget!
Rang Årets resultat
Rang i branche
120/132
"Bund 10%"
Rang i Danmark
342.703/344.193
"Bund 10%"
Legale ejere top 3
| 10-14.99% | Kmk Berlin A/S | DK |
| 5-9.99% | Cfc Holding Danmark Aps | DK |
| 5-9.99% | Engholm Finans Aps | DK |
Stamoplysninger baseret på CVR
| Navn | Medican A/S |
| Binavne | Medican Pharma A/S, Remedium A/S, Danish Cannabis Production A/S, Danish Cannabis Production Aps, Dansk Cannabis Produktion A/S, Dansk Cannabis Produktion Aps, Medcan A/S, Medcan Aps, Medicinsk Cannabis A/S, Medicinsk Cannabis Aps Vis mere |
| CVR | 39015684 |
| Adresse | Skovgårdsvej 27, 3200 Helsinge |
| Branche | Fremstilling af farmaceutiske præparater [212000] |
| Etableret | 12-10-2017 (6 år) |
| Første regnskabsperiode | 12-10-2017 til 30-06-2018 |
| Virksomhedsform | Aktieselskab |
| Antal ansatte | 4 (årsværk:4) |
| Reklamebeskyttelse | Nej |
| Regnskabsperiode | 01-07 til 30-06 |
| Selskabskapital | 2.111.463 DKK 1.788.709 DKK (19-02-2023 - 18-04-2023) 1.503.886 DKK (08-12-2022 - 18-02-2023) 1.245.479 DKK (07-07-2022 - 07-12-2022) 1.239.213 DKK (24-05-2022 - 06-07-2022) 1.215.977 DKK (08-03-2022 - 23-05-2022) |
| Vedtægter seneste | 28-04-2023 |
Medlem af brancherne
- Fremstilling af farmaceutiske præparaterNACE6 indeholdende 205 virk.
- Fremstilling af farmaceutiske præparaterNACE3 indeholdende 205 virk.
- Fremstilling af farmaceutiske råvarer og farmaceutiske præparaterNACE2 indeholdende 243 virk.
- FremstillingsvirksomhedNACE1 indeholdende 26.289 virk.
Formål
Selskabets formål er at producere Cannabis til medicinsk brug.
Regnskab
| 2022 | 2021 | 2020 | |
|---|---|---|---|
| Valuta/enhed | 000' DKK | 000' DKK | 000' DKK |
| Omsætning | - - | - - | - - |
| Bruttofortjeneste | -9.237 - | -10.145 - | -18.388 - |
| Årets resultat | -39.688 - | -15.037 - | -4.556 - |
| Egenkapital | 15.546 -50% | 31.397 -20% | 39.409 +72% |
| Balance | 39.606 -42% | 67.824 +33% | 51.048 +102% |
Ledelsesberetning
Financial review
The company's income statement for the year ended 30 June 2022 shows a loss of DKK 39,688,347, and the balance sheet at 30 June 2022 shows equity of DKK 15,546,276.
Year 2021/2022 for Medican has been in line with the general trend in the cannabis industry. The revenue has been lower than expected and regulatory delays are postponing the market entrance for the new products. There has been a perception between producers that the growth would increase in all segments, but the market for cannabis-based medicines, magistral compounds with cannabinoids and full spectrum products have been almost flat in the main markets over the last 12-18 months. No new countries with significant markets have legalized medical cannabis in Europe, however, there are positive signals from several countries have disclosed intentions to setup new pilots or extended pilot programs for cannabis as opening of sales in recreational markets in Germany, Czech Republic and other countries opening up for a significant new market which will likely change the medicinal cannabis market structure.
The development in the industry has been extensive in the year with many new product introductions in Medican’s core market segment resulting in some pressure on sales prices. Simultaneously the production costs have increased as result of energy crises adding another layer of insecurity into the industry.
Access to capital remains one of the toughest issues for this emerging industry being capital intensive while new technologies are being continuously introduces and changing the landscape. Energy efficiency and product quality are the main drivers for the intensive research and development work done in the industry.
The combination of continuously oversupply outdated equipment and limited access to capital indicates a trend towards consolidation in the industry for the established players.
The fiscal year has equivalently challenged Medican resulting in instability during the year.
Followed by the recession and declining sales:
Medican reduced the organization in sales and in production.
Executive management and board have been replaced and adding another multiplier in the instability equation.
Withdraw product application for the flower product on the Danish market.
Finalized the oil product development with external contract manufacturer and preparing for entering the Germany and Danish market.
Scale down production on biomass to save energy, labor costs and other operational expenditures.
Sale of daughter companies in Holland and Uruguay.
The company's income statement for the year ended 30 June 2022 shows a loss of DKK 39,688,347, and the balance sheet at 30 June 2022 shows equity of DKK 15,546,276.
Year 2021/2022 for Medican has been in line with the general trend in the cannabis industry. The revenue has been lower than expected and regulatory delays are postponing the market entrance for the new products. There has been a perception between producers that the growth would increase in all segments, but the market for cannabis-based medicines, magistral compounds with cannabinoids and full spectrum products have been almost flat in the main markets over the last 12-18 months. No new countries with significant markets have legalized medical cannabis in Europe, however, there are positive signals from several countries have disclosed intentions to setup new pilots or extended pilot programs for cannabis as opening of sales in recreational markets in Germany, Czech Republic and other countries opening up for a significant new market which will likely change the medicinal cannabis market structure.
The development in the industry has been extensive in the year with many new product introductions in Medican’s core market segment resulting in some pressure on sales prices. Simultaneously the production costs have increased as result of energy crises adding another layer of insecurity into the industry.
Access to capital remains one of the toughest issues for this emerging industry being capital intensive while new technologies are being continuously introduces and changing the landscape. Energy efficiency and product quality are the main drivers for the intensive research and development work done in the industry.
The combination of continuously oversupply outdated equipment and limited access to capital indicates a trend towards consolidation in the industry for the established players.
The fiscal year has equivalently challenged Medican resulting in instability during the year.
Followed by the recession and declining sales:
Medican reduced the organization in sales and in production.
Executive management and board have been replaced and adding another multiplier in the instability equation.
Withdraw product application for the flower product on the Danish market.
Finalized the oil product development with external contract manufacturer and preparing for entering the Germany and Danish market.
Scale down production on biomass to save energy, labor costs and other operational expenditures.
Sale of daughter companies in Holland and Uruguay.
16-12-2022